Replies to post #85648 on Amarin Corp Plc (AMRN)

[Whalatane]

Gabor my wife would say re


- "DMCs must not only consider statistical stopping guidelines when making decisions regarding the early termination of a trial for benefit, but they also must consider the uptake and acceptance of the result by the clinical community. If the data are relatively insubstantial, clinicians are skeptical of the results, and the trial may be viewed as an unnecessary loss of time, resources and, potentially, lives." -

My wife ( who worked on clinical trials at Yale and recruits for Renal clinical trials in SF ) would say that with an address population as high as 70M in the US ( note to Raf for correcting ) and an equal amount in the EU ...for these two populations ..a total of 140m CAD patients in the R-IT indication ........that data on 23,500 patient years currently in R-IT must really "knock it out of the park "for the primary and ALL secondary endpoints

But hey ..thats what you and JL are so certain of, right ?

Kiwi